October 15, 2004, TxCell raised EUR10.5 million in a first round of financing. Five major investors - Auriga Partners, AXA Private Equity, BioAm, CDC and Seventure - took part in the deal. They joined existing shareholders Inserm-Transfert and the company's founders and senior management.

 March 6, 2008, TxCell raised EUR10.5 million in a second round of financing. This second round, led by TxCell's longstanding investors Auriga Partners, AXA Private Equity, Bioam Gestion, CDC Innovation and Seventure, will allow us to continue our development programs on Crohn's disease (Ovasave®) and rheumatoid arthritis (TX-RAD).

TxCell is proud to have the support of some strong investors.
For more information, see below.

Auriga Partners

Auriga Partners is an independent venture capital firm based in Paris, France. It invests in innovative, high-potential ventures in information & communication technology and life science at the seed or early development stage in Europe, North America and Israel. Auriga Partners manages three funds totaling over €330 million. On top of investing the necessary capital, Auriga Partners also provides its portfolio companies with its know-how in developing and solidifying executive teams, structuring companies, broadening their networks and creating strategic & corporate alliances.

For further information, please visit  http://www.aurigapartners.com/  

AXA Private Equity

AXA Private Equity - an AXA Investment Managers company - is one of the world's leading private equity firms. AXA Private Equity offers investors a broad selection of high performance funds for every market segment: Buyout, Expansion Capital, Venture Capital, Co-investments, Infrastructure, Mezzanine, Primary, Early Secondary and Secondary Funds of Funds. The firm manages and/or advises on more than $22 billion of funds on behalf of leading international investors. Backed by its offices in Paris, Frankfurt, London, Milan, New York and Singapore, AXA Private Equity stands out from the competition through the expertise of its teams and its wide international presence. The firm maintains a constant focus on transparency, performance and sustainable profitability.

For further information, please visit  http://www.axaprivateequity.fr

Bioam Gestion

Bioam Gestion is a venture capital firm based in Paris, France, focusing on early-stage investments in biotech and healthcare companies. Bioam Gestion invests in innovative companies with high growth potential coming from the French and European public and private life science research. Healthcare-sector investment focus includes biopharmaceuticals, medical instrumentation and diagnosis. The company currently manages €51 million through two funds.

For further information, please visit  http://www.bioam.fr/

CDC Innovation

Founded in 1996, CDC Innovation is an international venture capital firm with its head office in Paris and a local presence in the Silicon Valley and in Switzerland. With over 415 M€ currently under management, our focus is on venture investments at both the early and late stage, in two sectors: information technologies and life sciences. Our aim is to create value by providing talented entrepreneurs with the resources, experience, and network necessary to turn world-class technologies into great businesses.

For further information, please visit  http://www.cdcinnovation.com/

Seventure

Active partner of companies with high growth potential, Seventure Partners invests since 1997 in the innovative technology businesses, especially in French and European firms involved in the market of Information and Communication Technologies, as well as life sciences. Managing approximately €500M, Seventure Partners is one of the most active European Venture Capital's. Seventure Partners is a subsidiary of Natixis Private Equity, and is among the European leaders in Capital Investment. In life sciences, its 4 favored investment areas are Industrial Biotech & Cleantech, Medical Devices, Biopharmaceutics and Nutrition & Wellness. Nevertheless, Seventure Partners also invests in diagnosis, galenic improvements, environment, bio-energy, skin care, well-being and services.

For further information, please visit  http://www.seventure.fr/

Inserm Transfert Initiative